# Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

> **NCT04198766** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Inhibrx Biosciences, Inc** · enrollment: 296 (actual)

## Conditions studied

- Solid Tumor
- Non-Small Cell Lung Cancer
- Head and Neck Cancer
- Melanoma
- Gastric Cancer
- Renal Cell Carcinoma
- Urothelial Carcinoma

## Interventions

- **DRUG:** INBRX-106 - Hexavalent OX40 agonist antibody
- **DRUG:** pembrolizumab 200 mg
- **DRUG:** pembrolizumab 400 mg
- **DRUG:** Carboplatin AUC-5
- **DRUG:** Carboplatin AUC-6
- **DRUG:** Pemetrexed 500 mg/m2
- **DRUG:** Cisplatin 75mg/m2
- **DRUG:** Paclitaxel 200mg/m2
- **DRUG:** Nab paclitaxel 100mg/m2

## Key facts

- **NCT ID:** NCT04198766
- **Lead sponsor:** Inhibrx Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-10
- **Primary completion:** 2026-10-30
- **Final completion:** 2027-05-12
- **Target enrollment:** 296 (ACTUAL)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04198766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04198766, "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04198766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*